Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 11/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.56 |
| ▸ | MEF2D | Q14814 | 5/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | MMP1 | P03956 | 2/20 | 0.54 |
| ▸ | MMP2 | P08253 | 2/20 | 0.54 |
| ▸ | MMP9 | P14780 | 2/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | EP300 | Q09472 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10456019 | 0.85 | HDAC4 (0.75) | HDAC1HDAC4MEF2DFFAR1MMP1 | |
| (E)-N-Methoxycinnamamide SCHEMBL13527482 | 0.81 | ALDH1A1 (0.65) | HDAC1HDAC4MMP1MMP2MMP9 | |
| SCHEMBL10198772 | 0.79 | CA1 (0.49) | HDAC1HDAC4FFAR1CA1CA2 | |
| SCHEMBL11461243 | 0.79 | MAPT (0.59) | HDAC1HDAC4MEF2DFFAR1CA1 | |
| SCHEMBL11461242 | 0.79 | MAPT (0.59) | HDAC1HDAC4MEF2DFFAR1CA1 | |
| SCHEMBL7770347 | 0.78 | CA1 (0.83) | HDAC1FFAR1CA1CA2HDAC3 | |
| SCHEMBL9448718 | 0.78 | MAOB (0.69) | HDAC1CA1CA2 | |
| SCHEMBL9448716 | 0.78 | MAOB (0.69) | HDAC1CA1CA2 | |
| N-Benzylaniline SCHEMBL28648928 | 0.76 | HDAC4 (0.70) | HDAC1HDAC4MEF2DFFAR1MMP1 | |
| SCHEMBL8349161 | 0.75 | HDAC1 (1.00) | HDAC1HDAC4MEF2DHDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9795597-B2 | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-10-24 | — | — | US | disclosed |
| US-20170239274-A1 | COMBINATION | NOVARTIS PHARMA AG (CH) | 2017-08-24 | — | — | US | disclosed |
| US-20170189408-A1 | NOVEL PHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2017-07-06 | — | — | US | disclosed |
| US-20170020878-A1 | COMBINATION COMPRISING A BTK INHIBITOR AND AN AKT INHIBITOR | NOVARTIS AG (CH) | 2017-01-26 | — | — | US | disclosed |
| US-20160235714-A1 | ENZALUTAMIDE IN COMBINATION WITH AFURESERTIB FOR THE TREATMENT OF CANCER | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-08-18 | — | — | US | disclosed |
| US-20160228456-A1 | COMBINATION | NOVARTIS PHARMA AG (CH) | 2016-08-11 | — | — | US | disclosed |
| US-20160220547-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| US-9399021-B2 | Pharmaceutical composition | NOVARTIS AG (CH) | 2016-07-26 | — | — | US | disclosed |
| US-9271941-B2 | Pharmaceutical composition | NOVARTIS AG (CH) | 2016-03-01 | — | — | US | disclosed |
| US-20150342957-A1 | COMBINATION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-20150313906-A1 | COMBINATION | GLAXOSMITHKLINE LLC | 2015-11-05 | — | — | US | disclosed |
| US-9085622-B2 | Antigen binding proteins | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-07-21 | — | — | US | disclosed |
| US-8853408-B2 | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2014-10-07 | — | — | US | disclosed |
| US-20140154316-A1 | NOVEL PHARMACEUTICAL COMPOSITION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-06-05 | — | — | US | disclosed |
| US-20140037726-A1 | NOVEL PHARMACEUTICAL COMPOSITION | GLAXOSMITHKLINE LLC (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140018393-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | Glaxo Smith Kline LLC | 2014-01-16 | — | — | US | disclosed |
| US-20130156779-A1 | NOVEL ANTIGEN BINDING PROTEINS | GLAXO GROUP LIMITED (GB) | 2013-06-20 | — | — | US | disclosed |
| US-20120302579-A1 | CANCER TREATMENT METHOD | GLAXOSMITHKLINE LLC | 2012-11-29 | — | — | US | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170239274-A1 | COMBINATION | CYP17A1, HSD17B11, HSD17B1 | HDAC1 128/4885HDAC4 753/4885MEF2D 3836/4885 |
| US-20160220547-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3B | HDAC1 67/4885HDAC4 121/4885MEF2D 2840/4885 |
| US-20120302579-A1 | CANCER TREATMENT METHOD | MPL, TPO, PROKR1 | HDAC1 4523/4885HDAC4 3805/4885MEF2D 4863/4885 |
| US-20130156779-A1 | NOVEL ANTIGEN BINDING PROTEINS | CD2BP2, HSPBP1, LGALS3BP | HDAC1 3555/4885HDAC4 3147/4885MEF2D 3216/4885 |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | HDAC1 2055/4885HDAC4 3077/4885MEF2D 2767/4885 |
| US-20170020878-A1 | COMBINATION COMPRISING A BTK INHIBITOR AND AN AKT INHIBITOR | BTK, PIK3CD, PIK3CA | HDAC1 842/4885HDAC4 1224/4885MEF2D 2100/4885 |
| US-20140154316-A1 | NOVEL PHARMACEUTICAL COMPOSITION | PHOSPHO1, PLA2G2C, TTR | HDAC1 1261/4885HDAC4 1122/4885MEF2D 2474/4885 |
| US-20140018393-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3B | HDAC1 67/4885HDAC4 121/4885MEF2D 2840/4885 |
| US-20160228456-A1 | COMBINATION | CYP17A1, HSD17B11, HSD17B1 | HDAC1 143/4885HDAC4 994/4885MEF2D 4001/4885 |
| US-20160235714-A1 | ENZALUTAMIDE IN COMBINATION WITH AFURESERTIB FOR THE TREATMENT OF CANCER | AR, PIK3CA, NR5A1 | HDAC1 7/4885HDAC4 67/4885MEF2D 1024/4885 |
| US-20140037726-A1 | NOVEL PHARMACEUTICAL COMPOSITION | PHOSPHO1, PLA2G2C, TTR | HDAC1 1261/4885HDAC4 1122/4885MEF2D 2474/4885 |
| US-20150313906-A1 | COMBINATION | EZH2, BMI1, DOT1L | HDAC1 16/4885HDAC4 54/4885MEF2D 645/4885 |
| US-20170189408-A1 | NOVEL PHARMACEUTICAL COMPOSITION | TTR, PHOSPHO1, PLA2G2C | HDAC1 1427/4885HDAC4 1127/4885MEF2D 1800/4885 |
| US-20150342957-A1 | COMBINATION | PAICS, CA6, CA5A | HDAC1 67/4885HDAC4 27/4885MEF2D 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.